Biostem Technologies is filing to go public. They’re a regenerative medicine company focused on placental-derived allograft therapies for wound care and surgery. The headline: they’re aiming to raise

Revenue hit $6.2M in the nine months ended Sept 2024, up from $3.5M in the same period last year. But the bottom line is deep in the red—net loss widened to $7.8M from $2.3M, driven by a big jump in operating expenses. Here’s a key risk: they’re in default on a $4.1M convertible note and need to raise at least $6M to cure it. If the IPO doesn't get done or falls short, that default could trigger a cascade of financial pain, including accelerated repayment. Use of proceeds is straightforward—working capital and general corporate purposes. No flashy expansion plans. This raise is about keeping the lights on and funding ongoing commercialization of their wound care products. Bottom line: growing top line in a niche biotech space, but negative margins and a debt overhang make this a high-wire act. This IPO isn't about growth—it's about survival. One for risk-tolerant speculators only.

Revenue hit $6.2M in the nine months ended Sept 2024, up from $3.5M in the same period last year. But the bottom line is deep in the red—net loss widened to $7.8M from $2.3M, driven by a big jump in operating expenses.